Heparin-induced substrate behavior of antithrombin Cambridge II

Blood

Volumn 102, Issue 12, 2003, Pages 4028-4034

  Mushunje, Alec ^a   Zhou, Aiwu ^a   Carrell, Robin W ^a   Huntington, James A ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN CAMBRIDGE II; BLOOD CLOTTING FACTOR 10A; DODECYL SULFATE SODIUM; FONDAPARINUX; GLYCOSAMINOGLYCAN; HEPARIN; MUTANT PROTEIN; PENTASACCHARIDE; PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; GENE MUTATION; HUMAN; IONIC STRENGTH; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEINASE INHIBITION; STOICHIOMETRY; THROMBOPHILIA; THROMBOSIS; UNITED KINGDOM;

EID: 0344394518     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1560     Document Type: Article

References (44)

1. Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature, 1973;246:355-357.
2. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973;248:6490-6505.
3. Kurachi K, Fujikawa K, Schmer G, Davie EW. Inhibition of bovine factor IXa and factor Xabeta by antithrombin III. Biochemistry. 1976;15:373-377.
4. Gettins PGW, Patston PA, Olson ST. Serpins: Structure, Function and Biology. Austin, TX: R. G. Landes Co; 1996.
5. Huntington JA, Carrell RW. The serpins: nature's molecular mousetraps. Sci Prog. 2001;84:125-136.
6. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature. 2000;407:923-926.
7. Huntington JA, Gettins PG. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin. Biochemistry. 1998;37:3272-3277.
8. Huntington JA, Olson ST, Fan B, Gettins PG. Mechanism of heparin activation of antithrombin: evidence for reactive center loop preinsertion with expulsion upon heparin binding. Biochemistry. 1996;35:8495-8503.
9. Hood DB, Huntington JA, Gettins PG. Alpha 1-proteinase inhibitor variant T345R: influence of P14 residue on substrate and inhibitory pathways. Biochemistry. 1994;33:8538-8547.
10. Patston PA, Gettins P, Beechem J, Schapira M. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry. 1991;30:8876-8882.
11. Futamura A, Gettins PG. Serine 380 (P14) → glutamate mutation activates antithrombin as an inhibitor of factor Xa. J Biol Chem. 2000;275:4092-4098.
12. Frebelius S, Isaksson S, Swedenborg J. Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT beta. Arterioscler Thromb Vasc Biol. 1996;16:1292-1297.
13. Olson ST, Biork I. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction: elucidation from salt concentration effects. J Biol Chem. 1991;266:6353-6364.
14. Olson ST, Bjork I. Role of protein conformational changes, surface approximation and protein cofactors in heparin-accelerated antithrombin-proteinase reactions. Adv Exp Med Biol. 1992;313:155-165.
15. Carrell RW, Stein PE, Fermi G, Wardell MR. Biological implications of a 3 A structure of dimeric antithrombin. Structure. 1994;2:257-270.
16. Schreuder HA, de Boer B, Dijkema R, et al. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol. 1994;1:48-54.
17. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci U S A. 1997;94:14683-14688.
18. Schechter I, Berger A. On the size of the active site in proteases, I: papain. Biochem Biophys Res Commun. 1967;27:157-162.
19. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med. 1975;292:146-151.
20. Abildgaard U. Antithrombin and Related Inhibitors of Coagulation. In: Poller L, ed. Anonymous Recent Advances in Blood Coagulation. Edinburgh, Scotland: Churchill Livingstone; 1981:146.
21. Harper PL, Luddington RJ, Daly M, et al. The incidence of dysfunctional antithrombin variants; four cases in 210 patients with thromboembolic disease. Br J Haematol. 1991;77:360-364.
22. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994;87:106-112.
23. Perry DJ, Daly M, Harper PL, et al. Antithrombin Cambridge II, 384 Ala to Ser: further evidence of the role of the reactive centre loop in the inhibitory function of the serpins. FEBS Lett. 1991;285:248-250.
24. Perry DJ, Daly ME, Tait RC, et al. Antithrombin cambridge II (Ala384Ser): clinical, functional, and haplotype analysis of 18 families. Thromb Haemost. 1998;79:249-253.
25. Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997;77:197-211.
26. Pelitou M, Lormeau JC, Choay J. A new synthetic pentasaccharide with increased anti-factor Xa activity: possible role for anionic clusters in the interaction of heparin and antithrombin III. Semin Thromb Hemost. 1991;17(suppl 2):143-146.
27. Fan B, Crews BC, Turko IV, Choay J, Zettlmeissl G, Gettins P. Heterogeneity of recombinant human antithrombin III expressed in baby hamster kidney cells: effect of glycosylation differences on heparin binding and structure. J Biol Chem. 1993;268:17588-17596.
28. Garone L, Edmunds T, Hanson E, et al. Anti-thrombin-heparin affinity reduced by fucosylation of carbohydrate at asparagine 155. Biochemistry. 1996;35:8881-8889.
29. Bruce D, Perry DJ, Borg JY, Carrell RW, Wardell MR. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn→Asp). J Clin Invest. 1994;94:2265-2274.
30. Nordenman B, Nystrom C, Bjork I. The size and shape of human and bovine antithrombin III. Eur J Biochem. 1977;78:195-203.
31. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol. 1993;222:525-559.
32. Petitou M, Duchaussoy P, Driguez PA, Herault JP, Lormeau JC, Herbert JM. New synthetic heparin mimetics able to inhibit thrombin and factor Xa. Bioorg Med Chem Lett. 1999;9:1155-1160.
33. Olson ST. Heparin and Ionic strength-dependent conversion of antithrombin III from an inhibitor to a substrate of alpha-thrombin. J Biol Chem. 1985;260:10153-10160.
34. Pelitou M, Duchaussoy P, Jaurand G, et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540). J Med Chem. 1997;40:1600-1607.
35. Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 32701: comparison with the "synthetic pentasaccharide" (SR 90107/ORG 31540) and standard heparin. Circ Res. 1996;79:590-600.
36. Belzar KJ, Dafforn TR, Petitou M, Carrell RW, Huntington JA. The effect of a reducing-end extension on pentasaccharide binding by antithrombin. J Biol Chem. 2000;275:8733-8741.
37. Goodwin CA, Deadman JJ, Le Bonniec BF, Elgendy S, Kakkar VV, Scully MF. Heparin enhances the catalytic activity of des-ETW-thrombin. Biochem J. 1996;315(pt 1):77-83.
38. Skinner R, Chang WS, Jin L, et al. Implications for function and therapy of a 2.9 A structure of binary-complexed antithrombin. J Mol Biol. 1998;283:9-14.
39. Sheehan JP, Sadler JE. Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci U S A. 1994;91:5518-5522.
40. Han JH, Van Deerlin VM, Tollefsen DM. Heparin facilitates dissociation of complexes between thrombin and a reactive site mutant (L444R) of heparin cofactor II. J Biol Chem. 1997;272:8243-8249.
41. Gopel W, Gortner L, Kohlmann T, Schultz C, Moller J. Low prevalence of large intraventricular haemorrhage in very low birthweight infants carrying the factor V Leiden or prothrombin G20210A mutation. Acta Paediatr. 2001;90:1021-1024.
42. Gopel W, Ludwig M, Junge AK, Kohlmann T, Diedrich K, Moller J. Selection pressure for the factor-V-Leiden mutation and embryo implantation. Lancet. 2001;358:1238-1239.
43. Turko IV, Fan B, Gettins PG. Carbohydrate isoforms of antithrombin variant N135Q with different heparin affinities. FEBS Lett. 1993;335:9-12.
44. Turk B, Brieditis I, Bock SC, Olson ST, Bjork I. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry. 1997;36:6682-6691.